UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 5, 2020

PRESTIGE CONSUMER HEALTHCARE INC.

(Exact Name of Registrant as Specified in Charter)

001-32433 (Commission File Number)

20-1297589 (IRS Employer Identification No.)

660 White Plains Road, Tarrytown, New York 10591 (Address of Principal Executive Offices) (Zip Code)

(<u>914) 524-6800</u>

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

U Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Delaware (State or Other Jurisdiction of Incorporation)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Common stock, par value \$0.01 per share

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: Trading Symbol(s) PBH Title of each class

Name of each exchange on which registered New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2020, Prestige Consumer Healthcare Inc. (the "Company") announced financial results for the fiscal quarter and six months ended September 30, 2020. A copy of the press release announcing the Company's earnings results for the fiscal quarter and six months ended September 30, 2020 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On November 5, 2020, representatives of the Company began making presentations to investors regarding the Company's financial results for the quarter and six months ended September 30, 2020 using slides attached to this Current Report on Form 8-K as Exhibit 99.2 (the "Investor Presentation") and incorporated herein by reference. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the fiscal year ended March 31, 2021.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

See Exhibit Index immediately following the signature page.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By:

Dated: November 5, 2020

PRESTIGE CONSUMER HEALTHCARE INC.

/s/ Christine Sacco Christine Sacco Chief Financial Officer

Exhibit	Description
99.1	- Press Release dated November 5, 2020 announcing the Company's financial results for the fiscal quarter and six months ended September 30, 2020 (furnished only).
99.2	Investor Presentation in use beginning November 5, 2020 (furnished only).

Prestige Consumer Healthcare Inc. Reports Fiscal 2021 Second Quarter Results

- Revenue was \$237.4 Million in Second Quarter Fiscal 2021, Approximately Flat to Prior Year
- Diluted EPS of \$0.88 in Second Quarter Fiscal 2021; Non-GAAP Adjusted Diluted EPS of \$0.78 up 15% from Prior Year Q2 Non-GAAP Adjusted Diluted EPS
- Debt Paydown of \$74 million in Second Quarter Fiscal 2021
- Provides Full-Year Fiscal 2021 Outlook

TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-November 5, 2020-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2020.

"We achieved a strong second quarter performance, driven by our leading and trusted portfolio of brands. Our time-tested brand-building and diversified portfolio led to stable revenue that once again translated into strong earnings growth in the second quarter and allowed us to continue our strategy of debt reduction and disciplined capital allocation, all in spite of disruptions related to COVID-19" said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.

Second Fiscal Quarter Ended September 30, 2020

Reported revenues in the second quarter of fiscal 2021 decreased 0.3% to \$237.4 million versus \$238.1 million in the second quarter of fiscal 2020. Revenues decreased 0.5% excluding the impact of foreign currency. The revenue performance for the quarter was driven by stable consumption across the majority of the Company's portfolio, partially offset by reduced consumption for certain brands where the category has been disrupted by the COVID-19 virus.

Reported net income for the second quarter of fiscal 2021 totaled \$44.6 million, compared to the prior year quarter's net income of \$33.3 million. Diluted earnings per share of \$0.88 for the second quarter of fiscal 2021 compared to \$0.65 in the prior year comparable period. On a Non-GAAP basis, adjusted net income and adjusted diluted earnings per share for the second quarter of fiscal 2021 were \$39.5 million and \$0.78, respectively, compared to \$34.3 million and \$0.68 earnings per share in the prior year comparable period.

The adjustment of net income in the second quarter Fiscal 2021 related to the final regulations issued during the fiscal quarter for certain tax elements imposed under the domestic Tax Cuts and Jobs Act, which resulted in a one-time discrete benefit associated with the utilization of foreign tax credits. Adjustments to net income in the second quarter of Fiscal 2020 included costs associated with a new logistics provider and location, and the related income tax effects of the adjustments.

Six Months Ended September 30, 2020

Reported revenues for the first six months of Fiscal 2021 totaled \$466.8 million, a decrease of 0.7%, compared to revenues of \$470.2 million for the first six months of Fiscal 2020. The revenue performance for the first six months was driven by stable consumption across the majority of the Company's portfolio and a benefit associated with higher retailer order patterns to refill customer's supply chains. This was partially offset by reduced consumption for certain brands where the category has been impacted by the COVID-19 virus.

Reported net income for the first six months of fiscal 2021 totaled \$88.3 million versus the prior year comparable period net income of \$67.2 million. Diluted earnings per share were \$1.74 for the first six months of fiscal 2021 compared to \$1.31 per share in the prior year comparable period. Non-GAAP adjusted net income for the first six months of fiscal 2020 was \$83.2 million, versus the prior year comparable period's adjusted net income of \$68.2 million. Non-GAAP adjusted earnings per share were \$1.64 per share for the first six months of fiscal 2020 compared to \$1.33 in the first six months of the prior year.

The adjustment of net income in the six months of Fiscal 2021 related to the final regulations issued during the fiscal quarter for certain tax elements imposed under the domestic Tax Cuts and Jobs Act, which resulted in a one-time discrete benefit associated with the utilization of foreign tax credits. Adjustments to net income in the first six months of Fiscal 2020 included costs associated with a new logistics provider and location, and the related income tax effects of the adjustments.

Free Cash Flow and Balance Sheet

The Company's net cash provided by operating activities for second quarter Fiscal 2021 was \$52.1 million, an increase compared to \$50.2 million during the prior year comparable period. Non-GAAP adjusted free cash flow in the second quarter of Fiscal 2021 was \$43.1 million compared to \$47.2 million in the prior year. The change in free cash flow versus the prior year was attributable to capital expenditure investments, as anticipated. The Company's net cash position provided by operating activities for the first six months of Fiscal 2021 was \$127.3 million, an increase compared to \$103.0 million during the prior year. Non-GAAP adjusted free cash flow for the first six months of Fiscal 2021 was \$115.7 million compared to \$98.0 million in the first half of the prior year.

The Company's net debt position as of September 30, 2020 decreased to approximately \$1.5 billion and the Company's covenant-defined leverage ratio was 4.3x. During the quarter the Company paid down debt outstanding by \$74 million as it continued to maintain focus on debt reduction.

Segment Review

North American OTC Healthcare: Segment revenues increased to \$216.6 million for the second quarter of fiscal 2021, compared to the prior year comparable quarter's revenues of \$213.9 million. The second quarter fiscal 2021 revenue performance was driven by consumption growth across the majority of the segment's core brand portfolio, but partially offset by a reduction in consumption for certain brands where the category consumption levels have been disrupted by the COVID-19 virus.

For the first six months of the current fiscal year, reported revenues for the North American OTC Healthcare segment increased to \$427.2 million compared to \$424.7 million in the prior year comparable period. The increased revenue versus the prior year comparable period benefited from an increase in consumption levels for the majority of the Company's core brand portfolio as well as a benefit in the first quarter associated with higher retailer order patterns to refill customer's supply chains, partially offset by a reduction in consumption for certain brands where the category consumption levels have been impacted by the COVID-19 virus.

International OTC Healthcare: Segment fiscal second quarter 2021 revenues totaled \$20.8 million, compared to \$24.2 million reported in the prior year comparable period. Revenues versus the prior year

were impacted by reduced consumption for certain brands impacted by the COVID-19 virus such as Hydralyte, partially offset by a foreign currency benefit of approximately \$0.7 million.

For the first six months of the current fiscal year, reported revenues for the International OTC Healthcare segment were \$39.6 million versus the prior year's comparable period's revenues of \$45.6 million, driven by reduced consumption for certain brands impacted by the COVID-19 virus such as *Hydralyte*.

Commentary and Outlook for Fiscal 2021

Ron Lombardi, Chief Executive Officer, stated, "Our second quarter revenues were stable owing to the many strengths of our overall business, including our broadly diversified portfolio of leading brands, agile marketing strategy and significant ongoing growth in the eCommerce channel stemming from long-term investments. Our strong financial profile and disciplined capital allocation strategy allowed us to pay down \$74 million in debt in the second quarter, which further enables long-term capital allocation optionality."

"During the second quarter, we experienced more stable consumption and retailer order patterns. This stabilization enables us to offer a full-year outlook based on the trends we are seeing. For revenue, we anticipate FY'21 revenue of ~\$925M. This outlook is driven by positive growth in most core brands offset by consumer behaviors stemming from the COVID-19 virus affecting demand in certain categories such as cough and cold during the upcoming peak season. Most importantly we plan to continue to execute our strategy of long-term brand-building and growing sales across our portfolio of core brands," he continued.

"We expect our leading financial profile will translate into strong earnings growth for the year, owing to disciplined cost management, strong cash flow and continued emphasis on debt reduction. We are confident in our strategy that positions us well to withstand these challenges as evidenced by our first half results. Our brand-building efforts, financial profile and disciplined capital allocation approach will enable us to focus on long-term top- and bottom-line growth prospects that position us for continued success," he concluded.

	<u>Fiscal 2021 Full-Year Outlook</u>
Revenue	Approximately \$925 million
Adjusted E.P.S.	Approximately \$3.18
Free Cash Flow	\$207 million or more

Fiscal Second Quarter 2021 Conference Call, Accompanying Slide Presentation and Replay

The Company will host a conference call to review its second quarter and first half results today, November 5, 2020 at 8:30 a.m. ET. The toll-free dial-in numbers are 844-233-9440 for the U.S. & Canada and 574-990-1016 internationally. The conference ID number is 4199894. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at www.prestigeconsumerhealthcare.com. The slide presentation can be accessed from the Investor Relations page of the website by clicking on Webcasts and Presentations.

Telephonic replays will be available for approximately one week following the completion of the call and can be accessed at 855-859-2056 within North America and at 404-537-3406 from outside North America. The conference ID is 4199894.

Non-GAAP and Other Financial Information

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the "About Non-GAAP Financial Measures" section at the end of this earnings release.

Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "target," "guidance," "strategy," "outlook," "plans," "projection," "focus," "may," "will," "would," "expect," "anticipate," "believe", "positions," "enables," or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, adjusted earnings per share, and free cash flow, the Company's expectations regarding its ability to viithstand challenges from the COVID-19 outbreak, the Company's ability to execute on its brand-building strategy, and maintain or grow market share, and the Company's ability to position itself for continued success. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of the COVID-19 pandemic and business and economic conditions, consumer trends, the impact of the Company's third party manufacturers and logistics providers and suppliers to meet demand for its products and to reduce costs. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2020 and other periodic reports filed with the Securities and Exchange Commission.

About Prestige Consumer Healthcare Inc.

The Company markets and distributes brand name over-the-counter healthcare products throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's brands include Monistat® and Summer's Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® eye care products, DenTek® and The Doctor's® oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® sore throat treatments, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Efferdent® denture care products, Luden's® throat drops, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.

Prestige Consumer Healthcare Inc. Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited)

	(Unaudited)								
	Three Mo		Six Months Ended September 30,						
<u>(In thousands, except per share data)</u>	2020		2019	2020		2019			
Total Revenues	\$ 23	37,422	\$ 238,069	\$	466,816	\$	470,223		
Cost of Sales									
Cost of sales excluding depreciation		98,239	100,318		192,363		197,418		
Cost of sales depreciation		1,522	 1,000		2,924		1,987		
Cost of sales		9,761	 101,318		195,287		199,405		
Gross profit	1	87,661	 136,751		271,529		270,818		
Operating Expenses									
Advertising and marketing		38,341	38,667		66,091		73,468		
General and administrative		20,388	22,514		40,322		44,220		
Depreciation and amortization		6,029	 6,222		12,094		12,296		
Total operating expenses		64,758	 67,403		118,507		129,984		
Operating income		72,903	 69,348		153,022		140,834		
Other (income) expense									
Interest expense, net	:	21,266	24,477		43,207		49,497		
Other (income) expense, net		(259)	 859		(249)		1,275		
Total other expense		21,007	25,336		42,958		50,772		
Income before income taxes		51,896	44,012		110,064		90,062		
Provision for income taxes		7,307	 10,760		21,769		22,885		
Net income	\$	4,589	\$ 33,252	\$	88,295	\$	67,177		
Earnings per share:									
Basic	\$	0.89	\$ 0.66	\$	1.76	\$	1.32		
Diluted	\$	0.88	\$ 0.65	\$	1.74	\$	1.31		
Weighted average shares outstanding:									
Basic		50,330	50,455		50,297		51,073		
Diluted		50,661	 50,811		50,672		51,426		
Comprehensive income, net of tax:									
Currency translation adjustments		3,665	(3,584)		14,255		(3,808)		
Unrecognized gain on interest rate swaps		985	 		1,294				
Total other comprehensive income (loss)		4,650	 (3,584)		15,549		(3,808)		
Comprehensive income	\$	9,239	\$ 29,668	\$	103,844	\$	63,369		

Prestige Consumer Healthcare Inc. Condensed Consolidated Balance Sheets (Unaudited)

(Unaudited)	Carstern bar 20, 2020		March 31, 2020		
(<u>In thousands</u>)	September 30, 2020		March 31, 2020		
Assets					
Current assets					
Cash and cash equivalents		03 \$	94,760		
Accounts receivable, net of allowance of \$18,450 and \$20,194, respectively	122,2		150,517		
Inventories	114,0		116,026		
Prepaid expenses and other current assets	7,0		4,351		
Total current assets	269,8	53	365,654		
Property, plant and equipment, net	65,1	61	55,988		
Operating lease right-of-use assets	26,2	11	28,888		
Finance lease right-of-use assets, net	10,8	97	5,842		
Goodwill	577,9	19	575,179		
Intangible assets, net	2,481,2		2,479,391		
Other long-term assets	3,0		2,963		
Total Assets	\$ 3,434,3	06 \$	3,513,905		
Liabilities and Stockholders' Equity					
Current liabilities					
Accounts payable	\$ 55,4		62,375		
Accrued interest payable	7,5	15	9,911		
Operating lease liabilities, current portion	5,4		5,612		
Finance lease liabilities, current portion	2,6		1,220		
Other accrued liabilities	65,1		70,763		
Total current liabilities	136,1	20	149,881		
Long-term debt, net	1,548,1	00	1,730,300		
Deferred income tax liabilities	416,3	83	407,812		
Long-term operating lease liabilities, net of current portion	22,4		24,877		
Long-term finance lease liabilities, net of current portion	8,4	28	4,626		
Other long-term liabilities	24,6		25,438		
Total Liabilities	2,156,0	89	2,342,934		
Stockholders' Equity					
Preferred stock - \$0.01 par value					
Authorized - 5,000 shares					
Issued and outstanding - None		-	-		
Common stock - \$0.01 par value					
Authorized - 250,000 shares					
Issued - 53,941 shares at September 30, 2020 and 53,805 shares at March 31, 2020		39	538		
Additional paid-in capital	493,7		488,116		
Treasury stock, at cost - 3,779 shares at September 30, 2020 and 3,719 shares at March 31, 2020	(119,8		(117,623)		
Accumulated other comprehensive loss, net of tax	(28,6		(44,161)		
Retained earnings	932,3		844,101		
Total Stockholders' Equity	1,278,2		1,170,971		
Total Liabilities and Stockholders' Equity	\$ 3,434,3	06 \$	3,513,905		

Prestige Consumer Healthcare Inc. Condensed Consolidated Statements of Cash Flows (Unaudited)

(Una	ıdited)		
	Six Months	Ended September 30,	
(<u>In thousands)</u>	2020	201	9
Operating Activities			
Net income	\$ 88,	295 \$	67,177
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	15,		14,283
Loss on disposal of property and equipment		31	19
Deferred income taxes	3,	656	5,827
Amortization of debt origination costs		918	1,711
Stock-based compensation costs		356	3,902
Non-cash operating lease cost	3,	587	3,154
Interest expense relating to finance lease liability		09	_
Changes in operating assets and liabilities:			
Accounts receivable	29,	58	5,982
Inventories	3,	213	(6,400)
Prepaid expenses and other current assets	(2,4	76)	(3,128)
Accounts payable	(9,1	.83)	8,465
Accrued liabilities	(8,5	.25)	6,616
Operating lease liabilities	(3,4	46)	(3,398)
Other	(1	.18)	(1,210)
Net cash provided by operating activities	127,	.93	103,000
Investing Activities			
Purchases of property, plant and equipment	(11,6	19)	(5,822)
Net cash used in investing activities	(11,0	19)	(5,822)
Financing Activities			
Term loan repayments	(130,	00)	_
Borrowings under revolving credit agreement	(150,		30,000
Repayments under revolving credit agreement	(55,		(76,000)
Payments of finance leases		(12)	(70,000)
Proceeds from exercise of stock options		285	544
Fair value of shares surrendered as payment of tax withholding		42)	(880)
Repurchase of common stock		197)	(49,976)
Net cash used in financing activities	(186,		(96,312)
Effects of exchange rate changes on cash and cash equivalents		335	(491)
(Decrease) increase in cash and cash equivalents	(68,		375
Cash and cash equivalents - beginning of period	(68,		27,530
Cash and cash equivalents - end of period	\$ 26,	603 <u></u> \$	27,905
Interest paid	\$ 42,	\$	48,033
Income taxes paid	\$ 18,	18 \$	14,655

Prestige Consumer Healthcare Inc. Condensed Consolidated Statements of Income Business Segments (Unaudited)

		Three Months Ended September 30, 2020							
(<u>In thousands)</u>	North American OT Healthcare	С	International OTC Healthcare			Consolidated			
Total segment revenues*	\$ 2	16,575	\$ 20),847	\$	237,422			
Cost of sales		91,069	٤	3,692		99,761			
Gross profit	1	25,506	12	2,155		137,661			
Advertising and marketing		34,014	4	1,327		38,341			
Contribution margin	\$	91,492	\$	7,828	\$	99,320			
Other operating expenses						26,417			
Operating income					\$	72,903			

* Intersegment revenues of \$0.6 million were eliminated from the North American OTC Healthcare segment.

		Six Months Ended September 30, 202	0
(In thousands)	North American OTC Healthcare	International OTC Healthcare	Consolidated
Total segment revenues*	427,233	39,583	466,816
Cost of sales	178,896	16,391	195,287
Gross profit	248,337	23,192	271,529
Advertising and marketing	58,694	7,397	66,091
Contribution margin	\$ 189,643	\$ 15,795	\$ 205,438
Other operating expenses			52,416
Operating income			\$ 153,022
-1			

*Intersegment revenues of \$1.6 million were eliminated from the North American OTC Healthcare segment.

		Th	ree Months Ended September 30, 2	ths Ended September 30, 2019				
(In thousands)		North American OTC Healthcare	International OTC Healthcare		Consolidated			
Total segment revenues*	\$	213,878	\$ 24,191	\$	238,069			
Cost of sales		92,931	8,387		101,318			
Gross profit		120,947	15,804		136,751			
Advertising and marketing		34,595	4,072		38,667			
Contribution margin	\$	86,352	\$ 11,732	\$	98,084			
Other operating expenses					28,736			
Operating income				\$	69,348			

* Intersegment revenues of \$0.8 million were eliminated from the North American OTC Healthcare segment.

	_	S	ix Months Ended	September 30, 20	19	
(In thousands)		North American OTC Healthcare	International	OTC Healthcare		Consolidated
Total segment revenues*	\$	424,662	\$	45,561	\$	470,223
Cost of sales		181,742		17,663		199,405
Gross profit	_	242,920		27,898		270,818
Advertising and marketing		65,609		7,859		73,468
Contribution margin	\$	177,311	\$	20,039	\$	197,350
Other operating expenses						56,516
Operating income					\$	140,834

* Intersegment revenues of \$1.6 million were eliminated from the North American OTC Healthcare segment.

About Non-GAAP Financial Measures

In addition to financial results reported in accordance with GAAP, we disclose certain Non-GAAP financial measures ("NGFMs"), including, but not limited to, Non-GAAP Organic Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP Adjusted EPS, Non-GAAP Adjusted Gross Margin Procentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adju obtained absent these disclosures, because the supplemental data relating to our financial condition and results of operations provides additional ways to view our operation when considered with both our GAAP results and the reconciliations below. In addition, we believe that the presentation of each of these NGFMs is useful to investors for period-to-period comparisons of results in assessing shareholder value, and we use these NGFMs internally to evaluate the performance of our personnel and also to evaluate our operating performance and compare our performance to that of our competitors.

These NGFMs are not in accordance with GAAP, should not be considered as a measure of profitability or liquidity, and may not be directly comparable to similarly titled NGFMs reported by other companies. These NGFMs have limitations and they should not be considered in isolation from or as an alternative to their most closely related GAAP measures reconciled below. Investors should not rely on any single financial measure when evaluating our business. We recommend investors review the GAAP financial measures included in this earnings release. When viewed in conjunction with our GAAP results and the reconciliations below, we believe these NGFMs provide greater transparency and a more complete understanding of factors affecting our business than GAAP measures alone.

NGFMs Defined

We define our NGFMs presented herein as follows:

- Non-GAAP Organic Revenues: GAAP Total Revenues excluding impact of foreign currency exchange rates in the periods presented.
- Non-GAAP Organic Revenue Change Percentage: Calculated as the change in Non-GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic Revenues. Non-GAAP Adjusted Gross Margin: GAAP Gross Profit minus certain transition and other costs associated with new warehouse.
- Non-GAAP Adjusted Gross Margin Percentage: Calculated as Non-GAAP Adjusted Gross Margin divided by GAAP Total Revenues
- Non-GAAP EBITDA: GAAP Net Income (Loss) before interest expense, net, income taxes provision (benefit), and depreciation and amortization.
- Non-GAAP EBITDA Margin: Calculated as Non-GAAP EBITDA divided by GAAP Total Revenues.
- Non-GAAP Adjusted EBITDA: Non-GAAP EBITDA less certain transition and other costs associated with new warehouse Non-GAAP Adjusted EBITDA Margin: Calculated as Non-GAAP Adjusted EBITDA divided by GAAP Total Revenues.
- Non-GAAP Adjusted Net Income: GAAP Net Income (Loss) before certain transition and other costs associated with new warehouse, tax impact of adjustments, and normalized tax rate adjustment.
- Non-GAAP Adjusted EPS: Calculated as Non-GAAP Adjusted Net Income, divided by the weighted average number of common and potential common shares outstanding during the period.
- Non-GAAP Free Cash Flow: GAAP Net cash provided by operating activities less cash paid for capital expenditures.
- Non-GAAP Adjusted Free Cash Flow: Non-GAAP Free Cash Flow plus cash payments made for transition and other costs associated with new warehouse.
- Net Debt: Calculated as total principal amount of debt outstanding (\$1,560,000 at September 30, 2020) less cash and cash equivalents (\$26,603 at September 30, 2020). Amounts in thousands.

The following tables set forth the reconciliations of each of our NGFMs (other than Net Debt, which is reconciled above) to their most directly comparable financial measures presented in accordance with GAAP.

Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related Non-GAAP Organic Revenue Change percentage:

	Three Months Ended September 30,				Six Months Ended September 30			
	 2020 2019		2020			2019		
<u>(In thousands)</u>								
GAAP Total Revenues	\$ 237,422	\$	238,069	\$	466,816	\$	470,223	
Revenue Change	 (0.3)%				(0.7)%			
Adjustments:	 							
Impact of foreign currency exchange rates	_		624		_		(729)	
Total adjustments	 _		624		_		(729)	
Non-GAAP Organic Revenues	\$ 237,422	\$	238,693	\$	466,816	\$	469,494	
Non-GAAP Organic Revenue Change	 (0.5)%				(0.6)%			

Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Non-GAAP Adjusted Gross Margin percentage:

Three Months Ended September 30,					Six Months End	ded September 30,		
	2020		2019		2020		2019	
\$	237,422	\$	238,069	\$	466,816	\$	470,223	
\$	137,661	\$	136,751	\$	271,529	\$	270,818	
	58.0 %		57.4 %		58.2 %		57.6 %	
	_		1,407		_		1,407	
	_		1,407		_		1,407	
\$	137,661	\$	138,158	\$	271,529	\$	272,225	
	58.0 %		58.0 %		58.2 %		57.9 %	
	\$ \$ 	2020 \$ 237,422 \$ 137,661 \$ 58.0 % 	2020 \$ 237,422 \$ 137,661 58.0 % 	2020 2019 \$ 237,422 \$ 238,069 \$ 137,661 \$ 136,751 \$ 58.0 % 57.4 %	2020 2019 \$ 237,422 \$ 238,069 \$ \$ 137,661 \$ 136,751 \$ \$ 58.0 % 57.4 % \$ - 1,407 \$ \$ - 1,407 \$ \$ \$ 137,661 \$ 138,158 \$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	

(1) Items related to new warehouse represent costs to transition to the new warehouse and duplicate costs incurred during the transition.

Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:

	Three Months Er	ded Sep	tember 30,	Six Months Ended			ember 30,
	 2020		2019		2020		2019
(In thousands)							
GAAP Net Income	\$ 44,589	\$	33,252	\$	88,295	\$	67,177
Interest expense, net	21,266		24,477		43,207		49,497
Provision for income taxes	7,307		10,760		21,769		22,885
Depreciation and amortization	7,551		7,222		15,018		14,283
Non-GAAP EBITDA	\$ 80,713	\$	75,711	\$	168,289	\$	153,842
Non-GAAP EBITDA Margin	 34.0 %		31.8 %		36.1 %		32.7 %
Adjustments:		-					
Transition and other costs associated with new warehouse in Cost of Goods Sold (1)	_		1,407		_		1,407
Total adjustments	 _		1,407		_		1,407
Non-GAAP Adjusted EBITDA	\$ 80,713	\$	77,118	\$	168,289	\$	155,249
Non-GAAP Adjusted EBITDA Margin	 34.0 %		32.4 %		36.1 %		33.0 %

(1) Items related to new warehouse represent costs to transition to the new warehouse and duplicate costs incurred during the transition.

Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income and related Non-GAAP Adjusted Earnings Per Share:

	Three Months Ended September 30,					Six Months Ended September 30,						
	 2020	2020 Adjusted EPS		2019	2019 Adjusted EPS	 2020 20	20 Adjusted EPS		2019	2019 Adjusted EPS		
(In thousands, except per share data)												
GAAP Net Income	\$ 44,589	\$ 0.88	\$	33,252 \$	0.65	\$ 88,295 \$	1.74	\$	67,177 \$	1.31		
Adjustments:												
Transition and other costs associated with new warehouse in Cost of Goods Sold $^{\left(1\right)}$	_	_		1,407	0.03	_	_		1,407	0.03		
Tax impact of adjustments (2)	_	_		(344)	(0.01)	_	_		(344)	(0.01)		
Normalized tax rate adjustment (3)	(5,106)	(0.10)		_	_	(5,106)	(0.10)		_	_		
Total adjustments	(5,106)	(0.10)		1,063	0.02	(5,106)	(0.10)		1,063	0.02		
Non-GAAP Adjusted Net Income and Adjusted EPS	\$ 39,483	\$ 0.78	\$	34,315 \$	0.68	\$ 83,189 \$	1.64	\$	68,240 \$	1.33		

Note: Amounts may not add due to rounding. (1) Items related to new warehouse represent costs to transition to the new warehouse and duplicate costs incurred during the transition. (2) The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and deferred income tax expense (benefit) based on the specific nature of the specific Non-GAAP performance measure. (3) Income tax adjustment to adjust for discrete income tax items.

Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP Adjusted Free Cash Flow:

	Т	hree Months En	ded Septe	ember 30,	Six Months End	ed Sept	ember 30,
		2020		2019	 2020		2019
(In thousands)					 		
GAAP Net Income	\$	44,589	\$	33,252	\$ 88,295	\$	67,177
Adjustments:							
Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows		11,374		14,039	29,775		28,896
Changes in operating assets and liabilities as shown in the Statement of Cash Flows		(3,824)		2,932	9,223		6,927
Total adjustments		7,550		16,971	 38,998		35,823
GAAP Net cash provided by operating activities		52,139		50,223	 127,293		103,000
Purchases of property and equipment		(9,066)		(3,866)	 (11,619)		(5,822)
Non-GAAP Free Cash Flow		43,073		46,357	115,674		97,178
Transition and other payments associated with new warehouse ⁽¹⁾		_		810	_		810
Non-GAAP Adjusted Free Cash Flow	\$	43,073	\$	47,167	\$ 115,674	\$	97,988

(1) Payments related to new warehouse represent costs to transition to the new warehouse and duplicate costs incurred during transition.

Outlook for Fiscal Year 2021:

Reconciliation of Projected GAAP EPS to Projected Non-GAAP Adjusted EPS:

Projected FY'21 GAAP EPS	\$	3.28
Adjustments:		
Normalized tax rate adjustment for discrete income tax items ⁽¹⁾		(0.10)
Total Adjustments	-	(0.10)
Projected Non-GAAP Adjusted EPS	\$	3.18

(1) Income tax adjustment to adjust for discrete income tax items.

Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Free Cash Flow:

(In millions)	
Projected FY'21 GAAP Net cash provided by operating activities	\$ 232
Additions to property and equipment for cash	(25)
Projected Non-GAAP Free Cash Flow	\$ 207





Second Quarter FY 2021 Re

November 5th,

This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1 such as statements regarding the Company's expected financial performance, including revenues, EPS, and free cash flow; the Company's ability to adapt to and perform well in the current changing disrupted environment, including ensuring the health and safet employees and maintain business continuity; anticipated inventory reductions; the Company's ability to have a disciplined capital allocation strategy, reduce debt and create value; the expected market share and consumption trends for the Company's brands; and Company's disciplined capital allocation strategy. Words such as "trend," "continue," "will," "expect," "project," "anticipate," "likely," "estimate," "may," "should," "could," "would," and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company's expectations and beliefs and involve a number of known and unknown risks, uncertainties and c factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, the impact of the COVID-19 pandemic, including on economic and business conditions, government actions, consumer trends, retail management initiatives, and disruptions to the distribution and supply chain; competitive pressures; unexpected costs or liabilities; the financial condition of the Company's suppliers and customers; and other risks set forth in Part I, Ite: 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March 31, 2020. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required l applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether a result of new information, future events, or otherwise.

All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule or in our November 5, 2020 earnings release in the "About Non-GAAP Financial Measures" section.

PrestigeConsumer HEALTHCARE

- I. Strategic Priorities
- II. Financial Overview
- III. Performance Highlights

IV.FY 21 Outlook

PrestigeConsumer HEALTHCARE



Strategic Priorities

Strategy in Place for Value Creation


Long-Term Strategy	=	Brand-Building designed to grow categories and connect with consumers Strategy and tactics performing well in disrupted environment
Business Continuity	=	Continuity plans continue to protect service levels Investing in inventory has paid off in challenged supply environment
Agile Marketing	=	Pivoted marketing efforts and returned to normalized investment levels Benefited from investments in winning channels wherever consumers shop
Financial Profile & Cash Flow	=	Solid financial profile and cash flow generation Continued focus on debt reduction in Q2

Strategic Priorities Remain Intact

PrestigeConsumer HEALTHCARE



Key Financial Results for Second Quarter and 1HFY 21 Performar




FY 21 Second Quarter and 1H Consolidated Financial Summary

	3 Ma	onths Er	nded	6 Months Ended			1H Comments
Total Revenue Adj. Gross Margin ⁽³⁾ % Margin A&M % Total Revenue G&A % Total Revenue D&A Adj. Operating Income ⁽³⁾ % Margin Adj. Earnings Per Share ⁽³⁾	Q2 FY 21 \$ 237.4 137.7 58.0% 38.3 16.1% 20.4 8.6% 6.0 \$ 72.9 30.7% \$ 0.78	Q2 FY 20 \$ 238.1 138.2 58.0% 38.7 16.2% 22.5 9.5% 6.2 \$ 70.8 29.7% \$ 0.68	% Chg (0.3%) (0.4%) (0.8%) (9.4%) (3.1%) 3.0%	IH FY 21 \$ 466.8 271.5 58.2% 66.1 14.2% 40.3 8.6% 12.1 \$ 153.0 32.8%	1H FY 20 \$ 470.2 272.2 57.9% 73.5 15.6% 44.2 9.4% 12.3 \$ 142.2 30.2% \$ 133	% Chg (0.7%) (0.3%) (10.0%) (8.8%) (1.6%) 7.6%	 Organic Revenue⁽¹⁾ down slightly Broad & diverse portfolio offse consumption headwinds in CC disrupted categories Triple-digit eCommerce consu growth as consumers continue online Adjusted Gross Margin⁽³⁾ of 58.2% vs. PY A&M of 14.2% of Revenue Q2 investment returned to nor levels, as expected
Adj. Earnings Per Share ^{v-,} Adj. EBITDA ⁽³⁾ % Margin Dollar values in millions, except per sha	\$ 0.78 \$ 80.7 34.0%	\$ 0.68 \$ 77.1 32.4%	<u>14.7%</u> <u>4.6%</u>	\$ 1.64 \$ 168.3 36.1%	\$ 1.33 \$ 155.2 33.0%	23.3%	 G&A dollars down vs. PY Adjusted EPS⁽³⁾ up 23.3% vs. PY

PrestigeConsumer HEALTHCARE

Industry Leading Free Cash Flow Trends






Pandemic Efforts Enabling Strong Performance

Workforce	Supply Base	Service
iņi		5
Prioritize health & safety while staffing appropriately	Working closely with suppliers in dynamic environment	Continued for on service retailers
Prestige Consumer HEALTHCARE		гs

Diverse Portfolio Positioned To Benefit From Changing Environ




Winning in Consumer Shift to Online



Prestige Adapting to Win in Real-Time



PrestigeConsumer HEALTHCARE



Outlook: Staying the Strategic Course to Create Value

Top Line Trends	 Business and strategy remain well-positioned in changing environment Market share solid and growing during pandemic environment Anticipate FY 21 Reported Revenue of ~\$925 million Expect similar dollar performance to 1H; cough, cold, and travel remain u pressure
EPS	 Anticipate FY 21 EPS⁽⁵⁾ of ~\$3.18 Strong financial profile leading to increased profitability
Free Cash Flow & Allocation	 Anticipate FY 21 Free Cash Flow⁽⁶⁾ at or above \$207 million generated in FY Continue to execute disciplined capital allocation strategy Remain focused on debt reduction
restige Consumer HEALTHCARE	SECOND QUARTER FY 21 RESULTS



Appendix

- (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measure in the attached Reconciliation Schedules and / or our earnings release dated November 5, 2020 in the "About Non-GAAP Financial Measures" section.
- (2) Total company consumption is based on domestic IRI multi-outlet + C-Store retail sales for the period ending October 4, 2020, retail sales from other 3rd parties for certain untracked channels in North America for leading retailers, Australia consumption based on IMS data, and other international net revenues as a proxy for consumption.
- (3) Adjusted EPS, Adjusted Gross Margin, Adjusted Operating Income, EBITDA, EBITDA Margin, Free Cash Flow and Net Debt are Non-GAAP financial measures and are reconciled to their most closely related GAAP financial measures in the attached Reconciliation Schedules and / or in our earnings release dated November 5, 2020 in the "About Non-GAAP Financial Measures" section.
- (4) Leverage ratio reflects net debt / covenant defined EBITDA.
- (5) Adjusted EPS for FY 21 is a projected Non-GAAP financial measure, is reconciled to projected GAAP EPS in the attached Reconciliation Schedules and / or in our earnings release in the "About Non-GAAP Financial Measures" section and is calculated based on projected GAAP EPS plus adjustments relating to discrete income tax items.
- (6) Adjusted Free Cash Flow for FY 21 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Net Cash Provided by Operating Activities in the attached Reconciliation Schedules and / or in our earnings release in the "About Non-GAAP Financial Measures" section and is calculated based on projected Net Cash Provided by Operating Activities less projected capital expenditures.

PrestigeConsumer HEALTHCARE

Reconciliation Schedules

Organic Revenue Change

	Three Months Ended September 30,					Six Months Ende	d September 30,		
		2020		2019		2020		2019	
(In Thousands)							2		
GAAP Total Revenues	\$	237,422	\$	238,069	\$	466,816	\$	470,223	
Revenue Change		(0.3%)				(0.7%)			
Adjustments:									
Impact of foreign currency exchange rates				624		-		(729)	
Total adjustments	\$	(m)	\$	624	\$		\$	(729)	
Non-GAAP Organic Revenues	\$	237,422	\$	238,693	\$	466,816	\$	469,494	
Non-GAAP Organic Revenue Change	17	(0.5%)				(0.6%)			

Adjusted Gross Margin

	Three	Months Ended	Septemb	er 30,	Six Months Ended September 30,				
(In Thousands)		2020		2019		2020	2019		
GAAP Total Revenues	\$	237,422	\$	238,069	\$	466,816	\$	470,223	
GAAP Gross Profit	\$	137,661	\$	136,751	\$	271,529	\$	270,818	
GAAP Gross Profit as a Percentage of GAAP Total Revenue		58.0%		57.4%		58.2%	-	57.6%	
Adjustments:			-						
Transition and other costs associated with new warehouse ^(a)				1,407		14		1,407	
Total adjustments				1,407		-		1,407	
Non-GAAP Adjusted Gross Margin	\$	137,661	\$	138,158	\$	271,529	\$	272,225	
Non-GAAP Adjusted Gross Margin as a Percentage of GAAP Total Revenues		58.0%		58.0%		58.2%		57.9%	

Items related to new warehouse represent costs to transition to the new warehouse and duplicate costs incurred during the transition



Reconciliation Schedules (Continued)

Adjusted EBITDA Margin

	TI	hree Months End	led Sept	tember 30,	5	Six Months Ende	ed September 30,		
		2020		2019		2020		2019	
(In Thousands)							-	0.00.000.0000	
GAAP Net Income	\$	44,589	\$	33,252	\$	88,295	\$	67,177	
Interest expense, net		21,266		24,477		43,207		49,497	
Provision for income taxes		7,307		10,760		21,769		22,885	
Depreciation and amortization	12	7,551		7,222	- 50.	15,018		14,283	
Non-GAAP EBIIDA		80,713		75,711		168,289		153,842	
Non-GAAP EBITDA Margin	-	34.0%	_	31.8%		36.1%		32.7%	
Adjustments:									
Transition and other costs associated with new warehouse in Cost									
of Goods Sold (a)		-		1,407		6 - 8		1,407	
Total adjustments		12	-	1,407		-		1,407	
Non-GAAP Adjusted EBITDA	\$	80,713	\$	77,118	\$	168,289	\$	155,249	
Non-GAAP Adjusted EBITDA Margin		34.0%		32.4%		36.1%		33.0%	

a) Items related to new warehouse represent costs to transition to the new warehouse and duplicate costs incurred during the transition.

PrestigeConsumer HEALTHCARE

Adjusted Net Income & Adjusted EPS

	Three Months Ended September 30,				Six Months Ended September 30,				
	2020		2019		2020		2019		
	Net		Net		Net		Net		
	Income	EPS	Income	EPS	Income	EPS	Income	EPS	
(In Thousands, except per share data)		-							
GAAP Net Income	\$ 44,589	\$ 0.88	\$ 33,252	\$ 0.65	\$ 88,295	\$ 1.74	\$ 67,177	\$ 1.31	
Adjustments:	S. 07 07		de la						
Transition and other costs associated with new									
warehouse in Cost of Goods Sold ^(a)	-	-	1,407	0.03	-	-	1,407	0.03	
Tax impact of adjustments ^(b)	-	-	(344)	(0.01)	-	-	(344)	(0.01)	
Normalized tax rate adjustment (c)	(5,106)	(0.10)		-	(5,106)	(0.10)	-	(1)	
Total Adjustments	(5,106)	(0.10)	1,063	0.02	(5,106)	(0.10)	1,063	0.02	
Non-GAAP Adjusted Net Income and Adjusted EPS	\$ 39,483	\$ 0.78	\$ 34,315	\$ 0.68	\$ 83,189	\$ 1.64	\$ 68,240	\$ 1.33	

a) b) c) Items related to new warehouse represent costs to transition to the new warehouse and duplicate costs incurred during the transition. The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and defer income tax adjustment to adjust for discrete income tax items. nse (benefit) based on the specific nature of the specific Non-GAAP performance measure

PrestigeConsumer HEALTHCARE

Reconciliation Schedules (Continued)

Adjusted Free Cash Flow

	Three Months Ended September 30,			Six Months Ended September 30,				
	2020		2019		2020		2019	
(In Thousands)								
GAAP Net Income	\$	44,589	\$	33,252	\$	88,295	\$	67,177
Adjustments:								
Adjustments to reconcile net income to net								
cash provided by operating activities as shown in								
the Statement of Cash Flows		11,374		14,039		29,775		28,896
Changes in operating assets and liabilities as shown in the								
Statement of Cash Flows		(3,824)		2,932		9,223		6,927
Total adjustments		7,550	22 27	16,971	10	38,998	24 10	35,823
GAAP Net cash provided by operating activities		52,139		50,223		127,293		103,000
Purchase of property and equipment		(9,066)		(3,866)		(11,619)		(5,822)
Non-GAAP Free Cash Flow		43,073		46,357		115,674		97,178
Transition and other payments associated with new warehouse ^(a)	52 33	2		810	6 . 84	120		810
Non-GAAP Adjusted Free Cash Flow	\$	43,073	\$	47,167	\$	115,674	\$	97,988

a) Payments related to new warehouse represent costs to transition to the new warehouse and duplicate costs incurred during transition

PrestigeConsumer HEALTHCARE

Projected EPS

Projected FY'21 GAAP EPS	\$	3.28
Adjustments:		
Normalized tax rate adjustment for discrete income tax items (a)		(0.10)
Total Adjustments		(0.10)
Projected Non-GAAP Adjusted EPS	\$	3.18
	-	,

Income tax adjustment to adjust for discrete income tax item

Projected Free Cash Flow

(In millions)	
Projected FY'21 GAAP Net Cash provided by operating activities	\$ 232
Additions to property and equipment for cash	(25)
Projected Non-GAAP Adjusted Free Cash Flow	\$ 207

PrestigeConsumer HEALTHCARE